Nicolas Combes

Nicolas Combes

Auto-generated profile, based on publicly available information

Nicolas Combes

Congenital Cardiology Department, Clinique Pasteur , 45 av. Lombez, 31000 Toulouse

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
PAPascal Amedro
Pascal Amedro
AGArthur Gavotto
Arthur Gavotto
HHHelena Huguet
Helena Huguet
LSLuc Souilla
Luc Souilla
AHAnne-Cecile Huby
Anne-Cecile Huby
SGSophie Guillaumont
Sophie Guillaumont
Cardiopulmonary fitness in congenital heart disease (CHD) decreases faster than in the general population resulting in impaired health-related quality of life (HRQoL). As the standard of care seems insufficient to encourage and maintain fitness, an early hybrid cardiac rehabilitation programme could improve HRQoL in CHD. The QUALIREHAB multicentre, randomized, controlled trial evaluated and implemented a 12-week centre- and home-based hybrid cardiac rehabilitation programme, including multidisciplinary care and physical activity sessions. Adolescent and young adult CHD patients with impaired cardiopulmonary fitness were randomly assigned to either the intervention (i.e. cardiac rehabilitation) or the standard of care. The primary outcome was the change in HRQoL from baseline to 12-month follow-up in an intention-to-treat analysis. The secondary outcomes were the change in cardiovascular parameters, cardiopulmonary fitness, and mental health. The expected number of 142 patients was enroled in the study (mean age 17.4 ± 3.4 years, 52% female). Patients assigned to the intervention had a significant positive change in HRQoL total score [mean difference 3.8; 95% confidence interval (CI) 0.2; 7.3; P = .038; effect size 0.34], body mass index [mean difference −0.7 kg/m2 (95% CI −1.3; −0.1); P = .022; effect size 0.41], level of physical activity [mean difference 2.5 (95% CI 0.1; 5); P = .044; effect size 0.39], and disease knowledge [mean difference 2.7 (95% CI 0.8; 4.6); P = .007; effect size 0.51]. The per-protocol analysis confirmed these results with a higher magnitude of differences. Acceptability, safety, and short-time effect of the intervention were good to excellent. This early hybrid cardiac rehabilitation programme improved HRQoL, body mass index, physical activity, and disease knowledge, in youth with CHD, opening up the possibility for the QUALIREHAB programme to be rolled out to the adult population of CHD and non-congenital cardiac disease. The long-term beneficial effect of the 12-week centre-based and home-based hybrid cardiac rehabilitation programme on adolescents and young adults with CHD was observed on HRQoL (primary outcome), BMI, physical activity, and disease knowledge, opening up the possibility for the QUALIREHAB programme to be rolled out to the adult population of CHD and non-congenital cardiac disease. BMI, body mass index; CHD, congenital heart disease; HRQoL, health-related quality of life.

1 June 2023 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
VWVictor Waldmann
Victor Waldmann
FBFrancis Bessière
Francis Bessière
KGKevin Gardey
Kevin Gardey
MBMohamed Bakloul
Mohamed Bakloul
EBEmre Belli
Emre Belli
NCNicolas Combes
Nicolas Combes
Background: Ventricular arrhythmias and sudden death are recognized complications in tetralogy of Fallot. Electrophysiological studies (EPS) before pulmonary valve replacement (PVR), the most common reintervention in tetralogy of Fallot, could potentially inform therapy to improve arrhythmic outcomes. Methods: A prospective multicenter study was conducted to systematically assess EPS with programmed ventricular stimulation in patients with tetralogy of Fallot referred for PVR from January 2020 to December 2021. A standardized stimulation protocol was used across all centers. Results: A total of 120 patients were enrolled, mean age 39.2±14.5 years, 53.3% males. Sustained ventricular tachycardia was induced in 27 (22.5%) patients. When identifiable, the critical isthmus most commonly implicated (ie, in 90.0%) was between the ventricular septal defect patch and pulmonary annulus. Factors independently associated with inducible ventricular tachycardia were history of atrial arrhythmia (odds ratio, 8.56 [95% CI, 2.43–34.73]) and pulmonary annulus diameter >26 mm (odds ratio, 5.05 [95% CI, 1.47–21.69]). The EPS led to a substantial change in management in 23 (19.2%) cases: 18 (15.0%) had catheter ablation, 3 (2.5%) surgical cryoablation during PVR, and 9 (7.5%) defibrillator implantation. Repeat EPS 5.1 (4.8–6.2) months after PVR was negative in 8 of 9 (88.9%) patients. No patient experienced a sustained ventricular arrhythmia during 13 (6.1–20.1) months of follow-up. Conclusions: Systematically performing programmed ventricular stimulation in patients with tetralogy of Fallot referred for PVR yields a high rate of inducible ventricular tachycardia and carries the potential to alter management. It remains to be determined whether a standardized treatment approach based on the results of EPS will translate into improved outcomes. Registration: URL: https://clinicaltrials.gov/ct2/show/NCT04205461 ; Unique identifier: NCT04205461

1 January 2024 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
Roberto MenèRoberto Menè
Roberto Menè
SBSerge Boveda
Serge Boveda
DRDomenico Giovanni. Della Rocca
Domenico Giovanni. Della Rocca
VSVasileios Sousonis
Vasileios Sousonis
GVGiampaolo Vetta
Giampaolo Vetta
SCStéphane Combes
Stéphane Combes

1 October 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
SHSebastien Hascoet
Sebastien Hascoet
GSGrzegorz Smolka
Grzegorz Smolka
DBDavid Blanchard
David Blanchard
MKMartin Kloëckner
Martin Kloëckner
EBEric Brochet
Eric Brochet
BGBenoît Gérardin
Benoît Gérardin
Background: Transcatheter closure of a symptomatic prosthetic paravalvular leak (PVL) is feasible, but there is presently no conclusive evidence to show consistent efficacy. We aimed to identify predictors of clinical success after transcatheter PVL closure. Methods: Consecutive patients referred to 24 European centers for transcatheter PVL closure in 2017 to 2019 were included in a prospective registry ( Fermeture de Fuite ParaProthétique , FFPP). Clinical success was absence of any of the following within 1 month: re-admission for heart failure, blood transfusion, open-heart valvular surgery, and death. Results: We included 216 symptomatic patients, who underwent 238 percutaneous PVL closure procedures on the mitral (64.3%), aortic (34.0%), or tricuspid (1.7%) valve. Symptoms were heart failure, hemolytic anemia, or both in 48.9%, 7.8%, and 43.3% of patients, respectively. One, 2, and 3 leaks were treated during the same procedure in 69.6%, 26.6%, and 3.8% of patients, respectively. The PVL was pinpoint or involved 1/8 or 1/4 of the valve circumference in 18.6%, 52.4%, and 28.1% of cases, respectively. The most frequently used devices were the Vascular Plug 3, Ventricular Septal Defect Occluder, Vascular Plug 2, and Paravalvular Leak Device (45.0%, 16.6%, 14.2%, and 13.6% of cases, respectively). Successful device(s) implantation with leak reduction to ≤grade 2 was obtained in 85.0% of mitral and 91.4% of aortic procedures, respectively ( P =0.164); with major periprocedural adverse event rates of 3.3% and 1.2%, respectively ( P =0.371); and clinical success rates of 70.3% and 88.0%, respectively ( P =0.004). By multivariate analysis, technical failure, mechanical valve, and hemolytic anemia were independently associated with absence of clinical success (odds ratios [95% CIs], 7.7 [2.0–25.0]; P= 0.002; 3.6 [1.1–11.1]; P =0.036; and 3.7 [1.2–11.9]; P =0.025; respectively). Conclusions: Transcatheter PVL closure is efficient and safe in symptomatic patients but is associated with a lower clinical success rate in patients with hemolysis and/or a mechanical valve. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT05089136

1 May 2017 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
NCNicolas Combes
Nicolas Combes
NDNicolas Derval
Nicolas Derval
SHSebastien Hascoet
Sebastien Hascoet
AZAlexandre Zhao
Alexandre Zhao
DADenis Amet
Denis Amet
EMEloi Marijon
Eloi Marijon

21 May 2025 in European Heart Journal
Verified
Journal Article
Closed access
VWVictor Waldmann
Victor Waldmann
GDGuillaume Duthoit
Guillaume Duthoit
JPJean-Luc Pasquié
Jean-Luc Pasquié
LCLaure Champ-Rigot
Laure Champ-Rigot
MAMathieu Albertini
Mathieu Albertini
FBFrancis Bessière
Francis Bessière
Background and Aims: Current evidence on catheter ablation for patients with congenital heart disease (CHD) is derived from small, retrospective studies. This study aims to provide insights from a nationwide contemporary registry. Methods: This prospective study included all CHD patients referred for catheter ablation from 2020 to July 2024 across 28 French centres. The primary outcome was the rate of per-procedural acute success. Secondary outcomes included complications as well as freedom from arrhythmia recurrence. Results: A total of 1135 consecutive catheter ablation procedures were performed in 998 patients (mean age 46.1 ± 16 years, 55.5% male). The main primary clinical arrhythmias targeted were atrial flutter/tachycardia in 677 (59.6%), atrial fibrillation in 195 (17.2%), ventricular arrhythmia in 188 (16.6%), and atrioventricular reentrant tachycardia in 38 (3.3%), with significant variations in patterns observed based on the underlying substrate. Clinical arrhythmia was successfully ablated in 1071 patients (94.4%). The mean number of arrhythmias targeted per procedure was 1.5 ± 0.7, with overall acute success rates exceeding 90% for all arrhythmias except for ventricular arrhythmias (86.7%). Acute complication occurred in 43 procedures (3.8%), including 1 (0.1%) death. The overall 1- and 2-year recurrence-free rates were 77.3% (95% confidence interval 74.2%–80.4%) and 68.4% (95% confidence interval 64.7%–72.3%), respectively. Significant variations in recurrence rates were noted based on the type of arrhythmia and the underlying CHD. Conclusions: Catheter ablation in patients with CHD demonstrates highly favourable acute outcomes and a low complication rate. Recurrence rates during follow-up vary depending on the targeted arrhythmia and the underlying CHD. These findings should be considered in the benefit-risk assessment.